FDA Grants Fast Track Designation to Quoin's QRX003 for Peeling Skin Syndrome

summarizeSummary

Quoin Pharmaceuticals announced FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome, the first-ever for this rare disease and the second for QRX003. The company expects to initiate a Phase 2/3 study in 2H 2026, targeting approval in 2028.

check_boxKey Events · Product Development and Regulatory · QNRX

• FDA Fast Track Designation Granted

  FDA granted Fast Track Designation to QRX003 for Peeling Skin Syndrome, the first-ever for this rare disease and the second for QRX003 after Netherton Syndrome (March 11, 2026).

• Phase 2/3 Study Planned

  Quoin expects to initiate a Phase 2/3 study in 2H 2026, enrolling up to 12 pediatric and adult patients in the U.S. and Europe, with an interim data review at 24 weeks.

• Approval Target 2028

  Quoin is targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028.

• Regulatory Milestone Builds on IND Clearance

  This designation follows FDA clearance in July 2026 of Quoin's IND application for QRX003 in Peeling Skin Syndrome, the first IND ever submitted for the disease.

auto_awesomeAnalysis · QNRX · Life Sciences

The FDA has granted Fast Track Designation to QRX003 for Peeling Skin Syndrome, a rare genetic skin disease with no approved treatment. This marks the first-ever Fast Track designation for a PSS therapy and the second for QRX003 overall, following the Netherton Syndrome designation in March 2026. The designation enables more frequent FDA interactions, rolling review, and potential eligibility for Accelerated Approval and Priority Review. Quoin plans to initiate a Phase 2/3 study in 2H 2026, targeting approval in 2028. For a micro-cap company with a going-concern warning, this regulatory progress strengthens the lead asset's development path and supports the recent $50M private placement thesis.